How to Cite
Abstract
Merkel cell carcinoma (MCC) is a rare primary malignant skin tumor with epithelial and neuroendocrine differentiation. According to the Russian clinical recommendations, MCC accounts for around 650 new cases per year in Russia. Avelumab is a human IgG1 monoclonal antibody that targets cancer cells through the inhibition of the immune checkpoint protein PD-L1 and can be used as a 2nd line treatment of metastatic MCC (mMCC). The aim of the study is to conduct a clinical and economic evaluation of avelumab as a second-line treatment in patients with mMCC from the perspective of Russian health care. Methods. Standard chemotherapy regimens were considered as a comparator for avelumab. We proposed a mathematical model of MCC progression and calculated direct medical costs during 6 years of treatment. Incremental cost-effectiveness ratios for avelumab (vs chemotherapy) were compared with the corresponding ratios for another PD-1 inhibitor included in Vital and Essential Drug List (VEDL). Results. Life-years gained (LYG) for avelumab were 2.21 years, compared to 0.39 LYG for chemotherapy. The average costs of using avelumab were 9 156 731 RUB per patient, compared to 60 743 RUB when using chemotherapy. Incremental cost-effectiveness ratio (ICER) for avelumab (vs chemotherapy) was 5 012 867.70 RUB per one LYG, which was 54.8% lower than ICER for pembrolizumab (vs docetaxel) as a second-line treatment in patients with non-small cell lung cancer. ICER for avelumab vs chemotherapy was 11,940,043.38 RUB per one progression-free LYG, which was 40.9% lower than ICER for pembrolizumab (vs chemotherapy) as a treatment in patients with ipilimumab-refractory advanced melanoma.
References
Ассоциация онкологов России, Российское общество клинической онкологии, Ассоциация специалистов по проблемам меланомы. Клинические рекомендации Карцинома Меркеля. - 2018. Доступно по: http://cr.rosminzdrav.ru/#!/schema/730. Ссылка активна на: 21.10.2019.
International statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHo Version for 2016. [Internet]. [cited 2019 Oct 21]. Available from: https://icd.who.int/browse10/2016/.
Kaufman H., Russell J., Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. The Lancet oncology. 2016;17(10):1374-1385. DOI: 10.1016/s1470-2045(16)30364-3
Kaufman H., Russell J., Hamid O. et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after >1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6(1). DOI: 10.1186/s40425-017-0310-x
Bavencio label. FDA. [published 2017, cited 2019 oct 21]. Available from: https://www.accessdata.fda.gov/drugsatf-da_docs/label/2017/761049s002lbl.pdf.
Bavencio label. FDA. [published 2019, cited 2019 oct 21]. Available from: https://www.accessdata.fda.gov/drugsatf-da_docs/label/2019/761049s006lbl.pdf.
DAngelo s, Russell J., Lebbé C et al. Efficacy and safety of First-line Avelumab Treatment in Patients With stage IV Metastatic Merkel Cell Carcinoma. JAMA oncol. 2018;4(9):e180077. DOI: 10.1001/jamaoncol.2018.0077
Cowey C., Mahnke L., Espirito J et al. Real-World outcomes of Patients with Metastatic Merkel Cell Carcinoma treated with second-Line or Later Chemotherapy in A Community oncology setting in The United states. Value in Health. 2016;19(7):A717. DOI: 10.1016/j.jval.2016.09.2122
Becker J., Lorenz E., Ugurel s et al. evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 2017;8(45). DOI: 10.18632/oncotarget.19218
ФАС России. Данные о предельных размерах оптовых надбавок и предельных размерах розничных надбавок к ценам на жизненно необходимые и важнейшие лекарственные препараты, установленные в субъектах российской Федерации (данные за 1 квартал 2019 г.)., [Internet]. [cited 2019 May 10]. Available from: https://fas.gov.ru/documents/684978.
Gervais R., Le Caer H., Monnet I et al. second-Line oral Chemotherapy (Lomustine, Cyclophosphamide, etopo-side) Versus Intravenous therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed small Cell Lung Cancer: A Randomized, Phase II study of GFPC 0501. Clin Lung Cancer. 2015;16(2):100-105. DOI: 10.1016/j.cllc.2014.10.002
von Pawel J., Jotte R., spigel D et al. Randomized Phase III Trial of Amrubicin Versus topotecan As second-Line treatment for Patients With small-Cell Lung Cancer. Journal of Clinical oncology. 2014;32(35):4012-4019. DOI: 10.1200/jco.2013.54.5392
Etoposide oral: Uses, side effects, Interactions, Pictures, Warnings and Dosing - WebMD. [cited 2019 oct 21]. Available from: https://www.webmd.com/drugs/2/drug-8781/etoposide-oral/details.
Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. - М.: МНИОИ им. П.А. Герцена; 2018. Доступно по: http://www.oncology.ru/service/statistics/condition/2017.pdf. Ссылка активна на: 21.10.2019.
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). - М.: МНИОИ им. П.А. Герцена; 2018. Доступно по: http://www.oncology.ru/service/statistics/malignant_tumors/2017. pdf. Ссылка активна на: 21.10.2019.
Клинические рекомендации по назначению колониестимулирующих факторов с целью профилактики развития фебрильной нейтропении. 2014. 12 с. [Электронный ресурс]. режим доступа: http://www.oncology.ru/association/clinical-guidelines/2014/07.pdf.
Cox J.D., stetz J.A., Pajak T.F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EoRTC) // International Journal of Radiation Oncology Biology Physics. - 1995. - Т. 31. - № 5. - С. 1341-1346.
Инструкция по медицинскому применению лекарственного препарата для медицинского применения Зарсио (Филграстим). Государственный реестр лекарственных средств Министерства здравоохранения РФ [Internet]. Available from: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=82346e08-227d-48ac-bd35-d06893565360&t=.
Ribas A., Puzanov I., Dummer R. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology. 2015;16(8):908-918. DOI: 10.1016/s1470-2045(15)0008
Hamid O., Puzanov I., Dummer R et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refrac-tory advanced melanoma. Eur J Cancer. 2017;86:37-45. DOI: 10.1016/j.ejca.2017.07.022
Herbst R., Baas P., Kim D. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387(10027):1540-1550. DOI: 10.1016/s0140-6736(15)01281-7
Bharmal M. Covariate-adjusted indirect comparison of avelumab versus chemotherapy in patients with chemotherapy-refractory mMCC. 2019.
Bharmal M. Covariate-adjusted indirect comparison of avelumab versus chemotherapy in patients with MCC. 2017.
Клинические рекомендации. Карцинома Меркеля. 2018. 46 с. [Электронный ресурс]. Режим доступа: http://cr.rosminzdrav.ru/#!/recomend/730.
Инструкция по медицинскому применению лекарственного препарата для медицинского применения Китруда (Пембролизумаб). Государственный реестр лекарственных средств Министерства здравоохранения рФ [Электронный ресурс]., режим доступа: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9c37c6d1-d125-41bd-9997-bdf38763cf18&t=.
Инструкция по медицинскому применению лекарственного препарата для медицинского применения опдиво (ниволумаб). Государственный реестр лекарственных средств Министерства здравоохранения рФ [Электронный ресурс]., режим доступа: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=42413f12-c14a-42de-8f96-614626e78e68&t=.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020